2023
Top advances of the year: Neuro‐oncology
Barden M, Omuro A. Top advances of the year: Neuro‐oncology. Cancer 2023, 129: 1467-1472. PMID: 36825454, DOI: 10.1002/cncr.34711.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBrain tumorsRecent phase 3 trialAnti-PD-1 immunotherapyCentral nervous system dysfunctionSingle-agent pembrolizumabHigh-dose chemotherapyPhase 3 trialPrimary CNS lymphomaStem cell transplantationLong-term outcomesLimited therapeutic optionsNervous system dysfunctionOngoing clinical trialsClinical trial landscapeDrug Administration approvalBRAF V600E mutationExcellent disease controlConsolidation therapyCNS lymphomaImproved survivalLeptomeningeal metastasesTherapeutic optionsCell transplantationCraniospinal irradiationPatient population
2020
Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer
Malani R, Fleisher M, Kumthekar P, Lin X, Omuro A, Groves MD, Lin NU, Melisko M, Lassman AB, Jeyapalan S, Seidman A, Skakodub A, Boire A, DeAngelis LM, Rosenblum M, Raizer J, Pentsova E. Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer. Journal Of Neuro-Oncology 2020, 148: 599-606. PMID: 32506369, PMCID: PMC7438284, DOI: 10.1007/s11060-020-03555-z.Peer-Reviewed Original ResearchConceptsLeptomeningeal metastasesCSF cytologyCSF CTCsCTC enumerationCerebrospinal fluidIT trastuzumabPhase I/II dose escalation trialCentral nervous system compartmentTumor cellsHER2/neu positivityHER2/neu expressionDose-escalation trialHER2-positive cancersIntrathecal trastuzumabEscalation trialRadiographic responseTumor burdenPositive cancersNeu expressionNeu positivityConclusionOur studyPatientsDay 1Epithelial cancersCancer
2018
P05.10 Prospective evaluation of cerebrospinal fluid circulating tumor cells (CSF CTC) in patients with HER2 positive cancers and leptomeningeal metastases receiving treatment with intrathecal trastuzumab
Pentsova E, Malani R, Fleisher M, Lin X, Omuro A, Groves M, Lin N, Melisko M, Lassman A, Jeyapalan S, Boire A, DeAngelis L, Raizer J. P05.10 Prospective evaluation of cerebrospinal fluid circulating tumor cells (CSF CTC) in patients with HER2 positive cancers and leptomeningeal metastases receiving treatment with intrathecal trastuzumab. Neuro-Oncology 2018, 20: iii304-iii304. PMCID: PMC6144227, DOI: 10.1093/neuonc/noy139.336.Peer-Reviewed Original ResearchCSF CTCsLeptomeningeal metastasesCellSearch systemCTC enumerationCSF cytologyTreatment responsePhase I/II dose escalation trialDose-escalation trialPositive CSF cytologyCycles of treatmentHER2-positive cancersCycle 1Number of CTCsIntrathecal trastuzumabIT trastuzumabLM progressionEscalation trialIntrathecal therapyRadiographic responseVentricular reservoirRadiographic worseningProspective evaluationPositive cancersHER2 expressionCerebrospinal fluid
2017
CMET-04. CEREBROSPINAL FLUID CIRCULATING TUMOR CELLS (CSF CTC) FOR PATIENT MONITORING AND RESPONSE TO TREATMENT
Malani R, Fleisher M, Lin X, Omuro A, Groves M, Lin N, Melisko M, Lassman A, Jeyapalan S, Briggs S, DeAngelis L, Raizer J, Pentsova E. CMET-04. CEREBROSPINAL FLUID CIRCULATING TUMOR CELLS (CSF CTC) FOR PATIENT MONITORING AND RESPONSE TO TREATMENT. Neuro-Oncology 2017, 19: vi39-vi39. PMCID: PMC5692986, DOI: 10.1093/neuonc/nox168.153.Peer-Reviewed Original ResearchCSF CTCsLeptomeningeal metastasesCTC enumerationLM progressionCellSearch systemHER2 expressionTreatment responsePhase I/II dose escalation trialDose-escalation trialPositive CSF cytologyCycles of treatmentNumber of CTCsCycle 1IT trastuzumabCirculating Tumor CellsEscalation trialIntrathecal therapyRadiographic responseVentricular reservoirRadiographic worseningCSF cytologyEarly biomarkersHER2 analysisPatientsDay 1Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors
Lin X, Fleisher M, Rosenblum M, Lin O, Boire A, Briggs S, Bensman Y, Hurtado B, Shagabayeva L, DeAngelis LM, Panageas KS, Omuro A, Pentsova EI. Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors. Neuro-Oncology 2017, 19: 1248-1254. PMID: 28821205, PMCID: PMC5570249, DOI: 10.1093/neuonc/nox066.Peer-Reviewed Original ResearchConceptsDiagnosis of LMLeptomeningeal metastasesCSF CTCsCSF cytologyEpithelial tumorsMRI findingsOptimal cutoffInstitutional review board-approved prospective studyTumor cellsNegative predictive value 97ROC analysisRare cell capture technologyPositive predictive value 90Positive CSF cytologyCSF of patientsSolid tumor patientsPrevious pilot studyClinical suspicionProspective studyCytology examinationTumor patientsLarge cohortCerebrospinal fluidPatientsStandard MRICerebrospinal fluid circulating tumor cells (CSF CTC) for real-time patient monitoring and response to treatment.
Malani R, Fleisher M, Lin X, Omuro A, Groves M, Lin N, Melisko M, Lassman A, Jeyapalan S, Briggs S, DeAngelis L, Raizer J, Pentsova E. Cerebrospinal fluid circulating tumor cells (CSF CTC) for real-time patient monitoring and response to treatment. Journal Of Clinical Oncology 2017, 35: 11549-11549. DOI: 10.1200/jco.2017.35.15_suppl.11549.Peer-Reviewed Original ResearchCSF CTCsLeptomeningeal metastasesCellSearch systemTreatment responseCTC enumerationLM progressionCSF cytologyPhase I/II dose escalation trialDose-escalation trialPositive CSF cytologyCycles of treatmentCycle 1IT trastuzumabEscalation trialIntrathecal therapyRadiographic responseVentricular reservoirRadiographic worseningDisease progressionEarly biomarkersCerebrospinal fluidDay 1Colon cancerPotential biomarkersDiagnostic markerCerebrospinal Fluid Circulating Tumor Cells: A Novel Tool to Diagnose Leptomeningeal Metastases from Epithelial Tumors (P5.170)
Lin X, Fleisher M, Rosenblum M, lin O, Briggs S, Boire A, Bensman Y, Hurtado B, DeAngelis L, Panageas K, Shagabayeva L, Omuro A, Pentsova E. Cerebrospinal Fluid Circulating Tumor Cells: A Novel Tool to Diagnose Leptomeningeal Metastases from Epithelial Tumors (P5.170). Neurology 2017, 88 DOI: 10.1212/wnl.88.16_supplement.p5.170.Peer-Reviewed Original Research
2015
Prospective validation of cerebrospinal fluid (CSF) circulating tumor cells (CTC) to diagnose leptomeningeal metastasis (LM) from epithelial tumors.
Lin X, Fleisher M, Omuro A, Shagabayeva L, Pentsova E. Prospective validation of cerebrospinal fluid (CSF) circulating tumor cells (CTC) to diagnose leptomeningeal metastasis (LM) from epithelial tumors. Journal Of Clinical Oncology 2015, 33: 2072-2072. DOI: 10.1200/jco.2015.33.15_suppl.2072.Peer-Reviewed Original ResearchLeptomeningeal metastasesCerebrospinal fluidProspective validationEpithelial tumorsTumor cellsMetastasisDetection of cerebral spinal fluid (CSF) circulating melanoma cells (CMC) for the diagnosis of melanoma leptomeningeal metastasis (LM).
Lin X, Fleisher M, Shagabayeva L, Omuro A, Pentsova E. Detection of cerebral spinal fluid (CSF) circulating melanoma cells (CMC) for the diagnosis of melanoma leptomeningeal metastasis (LM). Journal Of Clinical Oncology 2015, 33: e13061-e13061. DOI: 10.1200/jco.2015.33.15_suppl.e13061.Peer-Reviewed Original Research
2014
AT-47PHASE I TRIAL OF INTRATHECAL TRASTUZUMAB IN HER2 POSITIVE LEPTOMENINGEAL METASTASES
Raizer J, Pentsova E, Omuro A, Lin N, Nayak L, Quant E, Kumthekar P. AT-47PHASE I TRIAL OF INTRATHECAL TRASTUZUMAB IN HER2 POSITIVE LEPTOMENINGEAL METASTASES. Neuro-Oncology 2014, 16: v19-v19. PMCID: PMC4217826, DOI: 10.1093/neuonc/nou237.46.Peer-Reviewed Original ResearchHER2-positive breast cancerPositive breast cancerLeptomeningeal metastasesDose levelsBreast cancerIntrathecal trastuzumabCentral nervous system penetrationPhase I clinical trialPhase II studyHumanized monoclonal antibodyIT trastuzumabMedian KPSII studyProgressive diseaseI trialMedian ageOmmaya reservoirCSF levelsAnaplastic ependymomaClinical trialsPatientsPK dataTherapeutic levelsIts TreatmentTrastuzumab
2013
Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors
Nayak L, Fleisher M, Gonzalez-Espinoza R, Lin O, Panageas K, Reiner A, Liu CM, DeAngelis LM, Omuro A. Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors. Neurology 2013, 80: 1598-1605. PMID: 23553479, PMCID: PMC3662321, DOI: 10.1212/wnl.0b013e31828f183f.Peer-Reviewed Original ResearchConceptsLeptomeningeal metastasesSolid tumorsCSF CTCsCSF pleocytosisLumbar punctureConventional cytologyRare cell capture technologyEarly diagnostic confirmationInitial MRI evaluationRepeat lumbar puncturePresence of CTCsClinical suspicionMRI evaluationPatient cohortDiagnostic confirmationCSF samplesPatientsTumorsCTC resultsTumor cellsPilot studyPleocytosisMetastasisCTCsPuncture
2012
Leptomeningeal Metastasis from Non-small Cell Lung Cancer: Survival and the Impact of Whole Brain Radiotherapy
Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM. Leptomeningeal Metastasis from Non-small Cell Lung Cancer: Survival and the Impact of Whole Brain Radiotherapy. Journal Of Thoracic Oncology 2012, 7: 382-385. PMID: 22089116, DOI: 10.1097/jto.0b013e3182398e4f.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCranial IrradiationDose Fractionation, RadiationFemaleFollow-Up StudiesHumansImage Processing, Computer-AssistedLung NeoplasmsLymphatic MetastasisMaleMeningeal CarcinomatosisMiddle AgedNeoplasm Recurrence, LocalPrognosisRetrospective StudiesSurvival RateConceptsNon-small cell lung cancerWhole brain radiotherapyCell lung cancerLeptomeningeal metastasesTyrosine kinase inhibitorsLandmark analysisIT chemotherapyBrain radiotherapyIntrathecal therapyMedian survivalLung cancerEGFR mutationsEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsMedian age 59 yearsReceptor tyrosine kinase inhibitorsMedian overall survivalAge 59 yearsOptimal therapeutic approachSurvival of patientsDevastating complicationOverall survivalLeptomeningeal carcinomatosisRetrospective reviewRetrospective study
2010
Neurological Complications of Non-Hodgkin Lymphoma
Khasraw M, Noy A, Gilbert M, Omuro A. Neurological Complications of Non-Hodgkin Lymphoma. 2010, 267-285. DOI: 10.1007/978-1-4419-7668-0_16.Peer-Reviewed Original ResearchNon-Hodgkin lymphomaPeripheral nervous systemBrain metastasesCNS involvementCNS prophylaxisDirect complicationsNeurological complicationsParaneoplastic disordersPeripheral neuropathyLeptomeningeal metastasesNeurological symptomsHodgkin's lymphomaRisk factorsNervous systemComplicationsNHLLymphomaMetastasisInvolvementMyelopathyPlexopathyProphylaxisNeuropathyDirect involvementSymptoms
2005
Ventriculoperitoneal shunt in patients with leptomeningeal metastasis
Omuro AM, Lallana EC, Bilsky MH, DeAngelis LM. Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology 2005, 64: 1625-1627. PMID: 15883329, DOI: 10.1212/01.wnl.0000160396.69050.dc.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrainBrain NeoplasmsBreast NeoplasmsCarcinomaFemaleHumansHydrocephalusIntracranial HypertensionLung NeoplasmsMagnetic Resonance ImagingMaleMeningeal NeoplasmsMiddle AgedNeoplasm MetastasisPalliative CarePrognosisSubarachnoid SpaceSurvival RateTomography, X-Ray ComputedTreatment OutcomeVentriculoperitoneal ShuntConceptsLeptomeningeal metastasesPrognosis of LMEffective palliative toolMedian overall survivalProcedure-related mortalityVP shunt placementOverall survivalIntracranial hypertensionShunt placementVentriculoperitoneal shuntVP shuntPalliative toolSubdural hematomaShunt malfunctionPatientsMetastasisShuntHigh incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib
Omuro AM, Kris MG, Miller VA, Franceschi E, Shah N, Milton DT, Abrey LE. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 2005, 103: 2344-2348. PMID: 15844174, DOI: 10.1002/cncr.21033.Peer-Reviewed Original ResearchConceptsNonsmall cell lung carcinomaCentral nervous systemDisease recurrenceLong-term outcomesCell lung carcinomaBrain metastasesCNS metastasesLeptomeningeal metastasesLung carcinomaHigh incidenceAdvanced nonsmall cell lung carcinomaEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsMedian Karnofsky performance scoreMemorial Sloan-Kettering Cancer CenterMedian overall survival periodReceptor tyrosine kinase inhibitorsInitial disease recurrenceKarnofsky performance scoreOverall survival periodInitial responseTyrosine kinase inhibitorsInitial siteNeurologic symptomsPartial response